Recent Winners On GuerillaStockTrading

Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days
Alert Price: $19.94
High Price: $20.75
Results: 4% in 13 Days
Alert Price: $31.53
High Price: $32.69
Results: 4% in 9 Days
Alert Price: $14.05
High Price: $14.55
Results: 4% in 21 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.


Top Catalysts For The Week Ending January 20 2017

Sanchez Energy = Eagleford Acquisition Doubles Drilling Inventory

Mobileye = Goldman Sachs Raised Mobileye To A Buy Rating

Tesla = Expanding Investment In Gigafactory by $350 Million, Adding 550 New Jobs To Make Model 3

AbbVie = Gets FDA Approval For Imbruvica

3D Systems = Hearing Takeover Rumors Circulating About GE

International Game Technology = Wins Big Contract From Svenska Spel in Sweden

WiLAN = Court of Appeals Grants WiLAN Positive Rulings In Case Against Ericsson

Gilead Sciences = Hearing Takeover Rumors Circulating

Juno = Hearing Juno Takeover Rumors Circulating

Fusion Telecommunications = Awarded 3-year $100K For Managed Cloud Services

Teva Pharmaceutical = Receives FDA Approval For Vantrela ER

EPAM Systems = Lands Giant UBS Multi-year Agreement Valued At Over $300 Million

Tutor Perini Building = Receives Notice of Intent To Award a $1.37 Billion Contract From Los Angeles County

Amicus Therapeutics = Hearing Takeover Rumors Circulating

CEMEX = Trump Build That Wall Play

Iridium Communications = Announces Successful First Launch For Space-Based ADS-B Network

Applied Optoelectronics = Play On Switch From Copper To Optical Interconnect Inside Datacenters

3D Systems = Expands its Virtual Surgical Planning Service to Include Cranial Applications

Trading Lessons

Mainstream Financial News


Valeant Pharmaceuticals Announces Positive Results of Second Phase 3 Study for Psoriasis

Follow Us on StockTwits

January 10, 2017: Valeant Pharmaceuticals announced positive results from a second confirmatory pivotal Phase 3, multicenter double-blind, randomized, vehicle-controlled clinical study to assess the safety and efficacy of IDP-118 (halobetasol propionate and tazarotene) lotion in the treatment of plaque psoriasis.

Within the Phase 3 study of 203 adult subjects with moderate to severe psoriasis, IDP-118 showed statistical significance (p January 9, 2017: Valeant Pharmaceuticals International said to be close to deal to sell Dendreon cancer business to China conglomerate Sanpower for about $750 million according to reports in the mainstream financial press.

January 3, 2017: Valeant Pharmaceuticals has formed a candle over candle reversal as bottom feeders dip their toes into the stock on takeover rumors that are circulating. Valeant Pharmaceuticals trades at a forward P/E of 2.9 in response to their unfavorable practice of buying old drugs and then hiking up the price to insane levels to maximize profit.

Valeant Pharmaceuticals market cap is just over $5 billion, and they’ll probably do about $10 billion in sales for 2016, so that’s a substantial discount for a company looking to takeover Valeant Pharmaceuticals.

The rumor is that Takeda may have resumed M&A talks with Valeant according to a report in the Spanish press. The report suggests that Takeda has secured financing so that it can resume talks. Source:

Some believe that this is a fake news story and thus fake rumor being spread about Takeda and Valeant Pharmaceuticals and you can read that opinion here:

Valeant Pharmaceuticals Stock Chart

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide.


Trading The News: Valeant Pharmaceuticals International In The News